Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06261814 · ClinicalTrials.gov registry record · Phase 2
Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver Tumors
A Phase 2 study of Liver Neoplasms, sponsored by john eisenbrey.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 266
- Enrollment target
- 1
- Study location
NCT06261814: Recruiting Phase 2 study of Liver Neoplasms, sponsored by john eisenbrey.
NCT06261814 is a Phase 2 study of Liver Neoplasms that is actively recruiting participants, run by john eisenbrey. The registered enrollment target is 266 participants, below the 445-participant average among 14 other Liver Neoplasms trials with a reported enrollment target (40% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06261814, a Phase 2 study of Liver Neoplasms, is actively recruiting participants, sponsored by john eisenbrey.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 266 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial evaluates the diagnostic performance of contrast-enhanced ultrasound (CEUS) for assessing treatment response in patients undergoing transarterial chemoembolization (TACE) for liver tumors. TACE is a hepatic artery embolization technique involving the injection of a blocking agent and a chemotherapy agent to treat liver cancers. Currently, contrast enhanced magnetic resonance imaging or computed tomography are used to assess disease response 1-2 months after TACE treatment, but ultrasound may be a less expensive, earlier alternative. CEUS is an imaging procedure that uses high-frequency sound waves to generate images of the body after administering Lumason, an imaging agent used to enhance visualization of blood flow on ultrasounds. CEUS is able to be performed during the TACE procedure, making it possible to evaluate treatment response earlier than standard techniques. CEUS may be an effective method to evaluate treatment response more accurately and much earlier than current standard evaluation methods.
Conditions Studied
Interventions
- OTHER Medical Chart Review
- PROCEDURE Contrast-Enhanced Ultrasound
- DRUG Sulfur Hexafluoride Lipid Microspheres
- PROCEDURE Transarterial Chemoembolization
Study Locations (1)
Pennsylvania
- Sidney Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 266 participants |
| Start Date | 2024-08-07 |
| Est. Completion | 2028-01-01 |
| Phase | Phase 2 |
What NCT06261814 shows while recruiting
NCT06261814 is an interventional study that assigns participants to a tested intervention. The registered 266 participants enrollment target is mid-sized for trials with a published cap, below the 445-participant average among 14 other Liver Neoplasms trials with a reported enrollment target (40% lower).
The record links to 1 condition, with Liver Neoplasms appearing as the primary indexed condition, and to 4 interventions - of which Medical Chart Review is the first listed.
NCT06261814 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06261814 about?
NCT06261814 is a clinical study titled "Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver Tumors". This phase II trial evaluates the diagnostic performance of contrast-enhanced ultrasound (CEUS) for assessing treatment response in patients undergoing transarterial chemoembolization (TACE) for liver tumors. TACE is a hepatic artery embolization technique involving the injection of a blocking agent...
What is the current status of trial NCT06261814?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 266 participants. The study started on 2024-08-07. Estimated completion is 2028-01-01.
What conditions does trial NCT06261814 study?
This clinical trial studies the following conditions: Liver Neoplasms.
What interventions are being tested in trial NCT06261814?
The interventions under investigation include: Medical Chart Review (OTHER), Contrast-Enhanced Ultrasound (PROCEDURE), Sulfur Hexafluoride Lipid Microspheres (DRUG), Transarterial Chemoembolization (PROCEDURE).
Who is sponsoring clinical trial NCT06261814?
This trial is sponsored by john eisenbrey, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06261814 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06261814's enrollment target sits among peer trials
266 4th of 14 higher than 11 of 14 other Liver Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Liver Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging
RECRUITING · Phase 2
-
CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer
COMPLETED · Phase 2
-
ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
RECRUITING · Phase 1
-
Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
RECRUITING
-
The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy
ACTIVE NOT RECRUITING · NA
-
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05098652 · 266 participants · NA
Coaching Dementia Caregivers to Master Care-Resistant Behavior
- NCT06088277 · 266 participants · NA
Texting to Reduce Human Immunodeficiency Virus (HIV) Risk
- NCT06312124 · 266 participants · NA
A Study of Opportunistic Salpingectomy to Prevent Ovarian Cancer
- NCT06560866 · 266 participants · NA
Disrupting SRFOH to Improve Substance Use and Mental Health Outcomes for Parents in Rural Regions
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI